Benign prostatic hyperplasia: pathophysiology and pharmacological treatment.
Recent studies have confirmed that alpha-blocker therapy and antihormonal therapy are effective and safe treatment modalities in patients with symptomatic benign prostatic hyperplasia. New data suggest that the clinical response to medical therapy lasts for at least 3 years without any increase in side effects during this period.
Madsen
F A
FA
Division of Urology, University of Wisconsin Hospital and Clinics, Madison, USA.
Bruskewitz
R C
RC
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology*
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride